$11.30
4.16%
Nasdaq, Fri, Jul 11 2025
ISIN
US1710774076
Symbol
CDXC

ChromaDex Corporation Stock price

$11.30
-2.77 19.69% 1M
+6.04 114.83% 6M
+6.00 113.01% YTD
+8.42 292.36% 1Y
+9.58 556.98% 3Y
+6.21 122.00% 5Y
+10.22 946.30% 10Y
+7.55 201.33% 20Y
Nasdaq, Closing price Fri, Jul 11 2025
-0.49 4.16%
ISIN
US1710774076
Symbol
CDXC
Industry

Key metrics

Basic
Market capitalization
$890.1m
Enterprise Value
$834.6m
Net debt
positive
Cash
$55.5m
Shares outstanding
78.4m
Valuation (TTM | estimate)
P/E
66.5 | 85.2
P/S
8.2 | 7.1
EV/Sales
7.7 | 6.6
EV/FCF
42.7
P/B
16.1
Financial Health
Equity Ratio
67.5%
Return on Equity
18.6%
ROCE
21.9%
ROIC
85.2%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$107.9m | $125.9m
EBITDA
$14.0m | $13.4m
EBIT
$13.2m | $9.5m
Net Income
$14.1m | $10.4m
Free Cash Flow
$19.5m
Growth (TTM | estimate)
Revenue
29.8% | 26.4%
EBITDA
513.6% | 57.4%
EBIT
402.8% | 22.3%
Net Income
499.7% | 21.6%
Free Cash Flow
332.3%
Margin (TTM | estimate)
Gross
62.5%
EBITDA
13.0% | 10.7%
EBIT
12.3%
Net
13.1% | 8.3%
Free Cash Flow
18.1%
More
EPS
$0.2
FCF per Share
$0.2
Short interest
4.2%
Employees
-
Rev per Employee
-
Show more

Is ChromaDex Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

ChromaDex Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a ChromaDex Corporation forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a ChromaDex Corporation forecast:

Buy
91%
Hold
9%

Financial data from ChromaDex Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
108 108
30% 30%
100%
- Direct Costs 40 40
25% 25%
37%
67 67
33% 33%
63%
- Selling and Administrative Expenses 49 49
0% 0%
45%
- Research and Development Expense 5.18 5.18
12% 12%
5%
14 14
514% 514%
13%
- Depreciation and Amortization 0.79 0.79
19% 19%
1%
EBIT (Operating Income) EBIT 13 13
403% 403%
12%
Net Profit 14 14
500% 500%
13%

In millions USD.

Don't miss a Thing! We will send you all news about ChromaDex Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ChromaDex Corporation Stock News

Neutral
Business Wire
4 months ago
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #InvestorRelations--ChromaDex Corp. (NASDAQ:CDXC), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it will change its corporate name to Niagen Bioscience, Inc. and trade under the new Nasdaq symbol “NAGE” effective at stock market open on Wednesday, March 19, 2025. As part ...
Neutral
Business Wire
4 months ago
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science of healthy aging, today announces that senior management will participate at the 37th Annual ROTH Conference. ChromaDex CEO, Rob Fried, will participate on the Longevity and Supplementation Panel on Monday, March 17, at 1...
Neutral
Seeking Alpha
4 months ago
ChromaDex Corporation shows strong revenue growth and profitability, driven by its NAD+ precursors and flagship product Niagen, despite high valuation and execution risks. Record-breaking financial performance includes a 37.41% revenue increase, $7.2 million net income, and expanded gross margins, with a significant e-commerce boost. The company faces challenges like supply chain issues, tariff...
More ChromaDex Corporation News

Company Profile

Chromadex Corp. is a nutraceutical company. The firm engages in acquiring, developing and commercializing proprietary-based ingredient technologies. It operates through the following segments: Ingredients, Consumer Products, and Analytical Reference Standards and Services. The Ingredients segment offers NIAGEN in an ingredient form to partners. The Consumer Products segment sells TRU NIAGEN to improve health by safely raising NAD levels. The Analytical Reference Standards and Services segment provides product regulatory approval and scientific advisory services to the clients in the food, supplement, and pharmaceutical industries. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in September 1999 and is headquartered in Los Angeles, CA.

Head office United States
CEO Robert Fried
Founded 1999
Website www.niagenbioscience.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today